HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 10-31-2013, 09:53 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Pazopanib, Pemetrexed and Crizotinib for Advanced Disease

Pazopanib, Pemetrexed and Crizotinib for Advanced Disease

A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies (2011-1142)
Summary

Using a combination of drugs may be more effective than using one drug alone for treating advanced breast cancer. Crizotinib (Xalkori) blocks a protein called ALK, which is involved in cancer cell growth and survival. It is approved to treat some types of non-small cell lung cancer. Pazopanib (Votrient) blocks the growth of blood vessels that supply nutrients needed for tumor growth. It is approved for the treatment of advanced kidney cancer. Pemetrexed (Alimta) blocks proteins that may cause tumors to grow. It is approved for the treatment of non-small cell lung cancer. The goal of this trial is to identify the highest tolerable dose and to study the safety of the combination of crizotinib and pazopanib; crizotinib and pemetrexed; and crizotinib, pazopanib and pemetrexed in patients with advanced breast cancer. Patients with other types of advanced cancer are also being enrolled in this study.
This is a Phase I trial
'lizbeth is offline   Reply With Quote
Old 05-28-2014, 10:16 PM   #2
StephN
Senior Member
 
StephN's Avatar
 
Join Date: Nov 2004
Location: Misty woods of WA State
Posts: 4,026
Re: Pazopanib, Pemetrexed and Crizotinib for Advanced Disease

Thanks for posting these!
I also believe that a drug combo should work better for most people. Will be interesting to see how the results come in on these.

There are too many pathways for one drug to be successful at finding and closing off.
__________________
"When I hear music, I fear no danger. I am invulnerable. I see no foe. I am related to the earliest times, and to the latest." H.D. Thoreau
Live in the moment.

MY STORY SO FAR ~~~~
Found suspicious lump 9/2000
Lumpectomy, then node dissection and port placement
Stage IIB, 8 pos nodes of 18, Grade 3, ER & PR -
Adriamycin 12 weekly, taxotere 4 rounds
36 rads - very little burning
3 mos after rads liver full of tumors, Stage IV Jan 2002, one spot on sternum
Weekly Taxol, Navelbine, Herceptin for 27 rounds to NED!
2003 & 2004 no active disease - 3 weekly Herceptin + Zometa
Jan 2005 two mets to brain - Gamma Knife on Jan 18
All clear until treated cerebellum spot showing activity on Jan 2006 brain MRI & brain PET
Brain surgery on Feb 9, 2006 - no cancer, 100% radiation necrosis - tumor was still dying
Continue as NED while on Herceptin & quarterly Zometa
Fall-2006 - off Zometa - watching one small brain spot (scar?)
2007 - spot/scar in brain stable - finished anticoagulation therapy for clot along my port-a-catheter - 3 angioplasties to unblock vena cava
2008 - Brain and body still NED! Port removed and scans in Dec.
Dec 2008 - stop Herceptin - Vaccine Trial at U of W begun in Oct. of 2011
STILL NED everywhere in Feb 2014 - on wing & prayer
7/14 - Started twice yearly Zometa for my bones
Jan. 2015 checkup still shows NED
2015 Neuropathy in feet - otherwise all OK - still NED.
Same news for 2016 and half of 2017. Boring ...
StephN is offline   Reply With Quote
Old 05-29-2014, 08:23 AM   #3
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: Pazopanib, Pemetrexed and Crizotinib for Advanced Disease

I checked again for a Phase II and realized the Phase I completes in 4 years - wow seems like a long time for Phase I.
'lizbeth is offline   Reply With Quote
Old 05-29-2014, 08:23 AM   #4
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: Pazopanib, Pemetrexed and Crizotinib for Advanced Disease

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by M.D. Anderson Cancer Center
Sponsor:
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

ClinicalTrials.gov Identifier:
NCT01548144
First received: March 5, 2012
Last updated: February 18, 2014
Last verified: February 2014
History of Changes


Purpose The goal of this clinical research study is to find the highest tolerable dose of the combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed) or of the combination of 3 study drugs that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied.
Crizotinib is designed to block a protein called ALK, which is involved in cancer cell growth and survival.
Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells.
Pemetrexed is designed to block proteins that may cause tumors to grow.


Condition Intervention Phase Advanced Cancers
Drug: Crizotinib (Xalkori)
Drug: Pazopanib
Drug: Pemetrexed
Phase 1

Study Type: Interventional Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment Official Title: A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies
Resource links provided by NLM:

MedlinePlus related topics: Cancer
Drug Information available for: Pemetrexed Pemetrexed disodium Pazopanib Crizotinib
U.S. FDA Resources


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]If not more than 33% of participants in cohort develop dose limiting toxicity (DLT), this cohort considered MTD. MTD defined by DLTs that occur in first cycle (4 weeks). DLT defined as: Clinically grade 3 or 4 non-hematologic toxicity. Grade 4 hematologic toxicity lasting 3 weeks or longer. Grade 4 nausea or vomiting > 5 days despite maximum anti-nausea regimens. Grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome; or any severe or life-threatening complication or abnormality not defined in the NCI-CTCAE v4.0 attributable to therapy.



Estimated Enrollment: 364 Study Start Date: April 2012 Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions Experimental: Crizotinib (Xalkori) + Pazopanib Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Dose Expansion Group: MTD from Phase 1.
Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
Dose Expansion Group: MTD from Phase 1.

Drug: Crizotinib (Xalkori) Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Dose Expansion Group: MTD from Phase 1.

Other Names:
  • PF-02341066
  • Xalkori

Drug: Pazopanib Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
Dose Expansion Group: MTD from Phase 1.

Other Name: GW786034
Experimental: Crizotinib (Xalkori) + Pemetrexed Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Dose Expansion Group: MTD from Phase 1.
Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.
Dose Expansion Group: MTD from Phase 1.

Drug: Crizotinib (Xalkori) Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Dose Expansion Group: MTD from Phase 1.

Other Names:
  • PF-02341066
  • Xalkori

Drug: Pemetrexed Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Expansion group starting dose: MTD from Phase 1.
Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.

Other Names:
  • LY231514
  • Alimta
  • MTA
  • Multitargeted Antifolate
  • NSC-698037

Experimental: Pazopanib + Pemetrexed Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
Expansion group starting dose: MTD from Phase 1.
Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Expansion group starting dose: MTD from Phase 1.

Drug: Pazopanib Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
Dose Expansion Group: MTD from Phase 1.

Other Name: GW786034
Drug: Pemetrexed Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Expansion group starting dose: MTD from Phase 1.
Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.

Other Names:
  • LY231514
  • Alimta
  • MTA
  • Multitargeted Antifolate
  • NSC-698037

Experimental: Crizotinib (Xalkori) + Pazopanib + Pemetrexed Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Dose Expansion Group: MTD from Phase 1.
Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
Dose Expansion Group: MTD from Phase 1.
Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.
Dose Expansion Group: MTD from Phase 1.

Drug: Crizotinib (Xalkori) Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Dose Expansion Group: MTD from Phase 1.

Other Names:
  • PF-02341066
  • Xalkori

Drug: Pazopanib Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
Dose Expansion Group: MTD from Phase 1.

Other Name: GW786034
Drug: Pemetrexed Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Expansion group starting dose: MTD from Phase 1.
Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.

Other Names:
  • LY231514
  • Alimta
  • MTA
  • Multitargeted Antifolate
  • NSC-698037


Show Detailed Description




Eligibility

Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria
Inclusion Criteria:
  • Patients with advanced cancer, either refractory to standard therapy or for which no effective standard therapy that increases survival for at least 3 months is available.
  • Patients must have measurable or evaluable disease, as defined by RECIST 1.1.
  • Women of child-bearing potential and men must agree to use adequate contraception.
  • ECOG performance status of 0 to 2.
  • Adequate organ functions: (Crizotinib plus Pazopanib arm A): Neutrophils > 1000/uL; Platelets ≥ 75,000/uL; Total bilirubin < or= 2 x ULN (upper limit of normal); ALT < or = 2.5 x ULN or < o r= 5 x ULN if liver metastases persist; Serum creatinine < 2 x ULN (Crizotinib plus Pemetrexed arm B, Pazopanib plus Pemetrexed arm C, Crizotinib plus Pazopanib plus Pemetrexed arm D) Neutrophils > 1500/uL; Platelets > or = 100,000/uL; Total bilirubin < or = 2 x ULN (upper limit of normal); ALT < or = 2.5 x ULN or < or = 5 x ULN if liver metastases persist; Calculated GFR > 45 mL/min.
  • Creatinine Clearance: The standard Cockcroft and Gault formula must be used to calculate CrCl for enrollment or dosing. Also include in the pre-treatment or baseline text portion of the protocol, the 'On Study Evaluations or During Treatment' for every Pemetrexed treatment day, and also capture in the study Schedule of Events. No dosage adjustment is needed in patients with creatinine clearance > 45 mL/min. Insufficient numbers of patients have been studied with creatinine clearance <45 mL/min to give a dose recommendation. Therefore, Pemetrexed should not be administered to patients whose creatinine clearance is <45 mL/min.
  • For pemetrexed arms: The ability to interrupt NSAIDs 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed.
  • The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol for all pemetrexed arms.
  • Expansion cohort only for arms containing crizotinib: arm A (Crizotinib plus Pazopanib) and arm B (Crizotinib plus Pemetrexed) and arm D (Crizotinib plus Pazopanib Plus Pemetrexed) but not arm C (Pazopanib plus Pemetrexed). Patients must have ALK abnormality including: translocation, ALK amplification, mutation and overexpression as determined by FISH, IHC, qPCR, qRT-PCR, array Comparative Genomic Hybridization or direct sequencing (aCGH). Or patients must have a c-Met abnormality; either c-Met amplification or c-Met mutation or patients must have the ROS1 translocation as determined by FISH.
Exclusion Criteria:
  • Patient receiving any concurrent chemotherapy.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics.
  • Symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris or congenital long QT syndrome.
  • Medical and/or psychiatric problems of sufficient severity to limit full compliance with the study or expose patients to undue risk.
  • Known anaphylactic or severe hypersensitivity to study drugs or their analogs.
  • Patient has failed to recover from any prior surgery within 4 weeks of study entry.
  • Patient is pregnant or lactating.
  • Patient has had any treatment specific for tumor control within 3 weeks of dosing with investigational drugs and cytotoxic agents, or within 2 weeks of cytotoxic agent given weekly, or within 6 weeks of nitrosoureas or mitomycin C, or within 5 half-lives of biological targeted agents with half-lives and pharmacodynamic effects lasting less than 5 days (that includes, but is not limited to, erlotinib, sorafenib, sunitinib, bortezomib, and other similar agents).
  • Patient has any signs of intestinal obstruction.
  • Patient is not able to swallow oral medication.
  • Patients receiving whole brain radiation within 14 days prior to the first dose of study drugs will be excluded. NOTE: Patients receiving palliative radiation (other than whole brain) before or during treatment may still be eligible as long as there are evaluable lesions that are not being irradiated.
  • Pemetrexed arms only: Presence of third space fluid which cannot be controlled by drainage.
  • Additional Exclusions for the 3 pazopanib containing arms (Crizotinib plus Pazopanib) and (Pazopanib plus Pemetrexed) and (Crizotinib plus Pazopanib plus Pemetrexed). 1. History of stroke or transient ischemic attack within 6 months prior to study enrollment. 2. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment. 3. Urine for proteinuria > or = 2+ (patients discovered to have > or = 2+ proteinuria on urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate < or = 1g of protein in 24 hours to be eligible).



Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01548144

Contacts
Contact: Ralph Zinner, MD, BA 713-563-1930


Locations
United States, Texas UT MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Ralph Zinner, MD,BA UT MD Anderson Cancer Center


More Information
Additional Information: UT MD Anderson Cancer Center Website

No publications provided

Responsible Party: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: NCT01548144 History of Changes Other Study ID Numbers: 2011-1142 Study First Received: March 5, 2012 Last Updated: February 18, 2014 Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center: Crizotinib
PF-02341066
Pazopanib
Gw786034
Pemetrexed
LY231514
Alimta
Multitargeted Antifolate
Advanced Cancers
Advanced Malignancies
MTA
NSC-698037


Additional relevant MeSH terms: Neoplasms
Folic Acid Antagonists
Pemetrexed
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antimetabolites, Antineoplastic
Antimetabolites


ClinicalTrials.gov processed this record on May 28, 2014
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 01:48 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2017, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter